Goldman Sachs Group Inc Homology Medicines, Inc. Transaction History

Goldman Sachs Group Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.53 - $1.14 $328 - $705	-619 Reduced 2.43%	24,853 $15,000
Q3 2023 May 14, 2024	BUY	$0.84 - $1.43 $519 - $885	619 Added 2.49%	25,472 $29,000
Q3 2023 Nov 14, 2023	SELL	$0.84 - $1.43 $814 - $1,387	-970 Reduced 3.67%	25,472 $29,000
Q2 2023 May 14, 2024	BUY	$0.83 - $1.12 $485 - $655	585 Added 2.26%	26,442 $23,000
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.12 $485 - $655	585 Added 2.26%	26,442 $23,000

Q1 2023 May 14, 2024	SELL	$0.91 - $1.69 $9,657 - $17,935	-10,613 Reduced 29.1%	25,857 $26,000
Q1 2023 May 11, 2023	SELL	$0.91 - $1.69 $9,657 - $17,935	-10,613 Reduced 29.1%	25,857 $26,000
Q4 2022 May 14, 2024	SELL	$1.09 - $2.04 $117,218 - $219,381	-107,540 Reduced 74.68%	36,470 $45,000
Q4 2022 Feb 13, 2023	SELL	$1.09 - $2.04 $117,218 - $219,381	-107,540 Reduced 74.68%	36,470 $45,000
Q3 2022 May 14, 2024	SELL	$1.55 - $3.01 $5,093 - $9,890	-3,286 Reduced 2.23%	144,010 $231,000
Q3 2022 Nov 10, 2022	SELL	$1.55 - $3.01 $5,093 - $9,890	-3,286 Reduced 2.23%	144,010 $0
Q2 2022 May 14, 2024	BUY	$1.39 - $3.12 $170,195 - $382,022	122,443 Added 492.67%	147,296 $291,000
Q2 2022 Aug 15, 2022	SELL	$1.39 - $3.12 $312,118 - $700,583	-224,546 Reduced 60.39%	147,296 $291,000
Q1 2022 May 16, 2022	SELL	$2.6 - $4.17 $746,132 - $1.2 Million	-286,974 Reduced 43.56%	371,842 $1.13 Million
Q4 2021 Feb 14, 2022	BUY	$3.64 - $7.78 $1.45 Million - $3.11 Million	399,702 Added 154.26%	658,816 $2.4 Million
Q3 2021 Nov 10, 2021	BUY	$6.01 - $8.71 $1.56 Million - $2.26 Million	259,114 New	259,114 $2.04 Million

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.